相关实验视频

Updated: Jul 20, 2025

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

Published on: May 31, 2024

伊索利基里通过Caspase 3/HMGB1/TLR4依赖信号通路改善了大鼠的性结肠炎

Zhiwei Miao¹, Mingjia Gu², Faisal Raza³

¹Department of Gastroenterology, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, 215600, China.

Current gene therapy

|August 1, 2023

概括

性结肠炎 (UC) 模型中,flavanol glycoside 类型的伊索利基里有效降低了肠道炎症和粘膜损伤. 它通过抑制caspase-3/HMGB1/TLR4信号通路而起作用,为UC提供了潜在的治疗方法.

科学领域:

药理学药理学是指药理学的学科.
胃肠病学胃肠病学
分子生物学分子生物学

背景情况:

伊索利基瑞是一种因其强大的抗炎性质而闻名的醇糖化物.
性结肠炎 (UC) 是一种慢性炎症性肠病,具有显著的未满足治疗需求.

研究的目的:

在UC的临床前模型中研究异素的抗炎作用.
阐明潜在的分子机制,重点关注caspase-3/HMGB1/TLR4通路.

主要方法:

已建立的三二硫酸 (TNBS) 诱导的大肠炎模型在老鼠中.
在Caco-2细胞中利用脂聚糖 (LPS) 诱导的炎症模型.
分析了蛋白质和基因表达,使用西式涂抹,实时PCR,免疫组织化学和免疫光.
对UC相关蛋白质水平进行了生物信息分析.

主要成果:

伊索利基里治疗显著改善了结肠炎症状,包括缩短结肠长度,疾病活性指数 (DAI) 和体重减轻.
观察到炎症调解剂 (例如IL-1β,TNF-α) 和氧化应激标志物 (MDA,SOD) 的水平降低.
抑制了TLR4下游通路 (MyD88,IRAK1,TRAF6,NF-κB,p38,JNK) 的关键组成部分和上游配体HMGB1在mRNA和蛋白质水平上.
生物信息分析显示,肠炎中HMGB1,TLR4和caspase-3的高表达.

结论:

伊索利奎里丁在体内和体外表现出显著的抗结肠炎和抗炎作用.
异基的治疗作用通过抑制caspase-3/HMGB1/TLR4信号通路进行介导.
伊索利基里为治疗性结肠炎提供了一个有前途的治疗候选药物.

关键词:

这就是HMGB1的特点.绝缘化素是什么意思在 TLR4 中,在每一个阶段.炎症性. 炎症性的.性结肠炎是一种

更多相关视频

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...